Broadening our portfolio with new projects and partnerships
Events during the third quarter 2025
New data on lecanemab were presented at the AAIC-congress focused on long-term efficacy and safety, real world evidence and subcutaneous dosing
Option, collaboration and license agreement signed with Novartis, with an upfront payment of USD 30 M. The agreement is for a potential treatment combining BioArctic's BrainTransporter technology with a Novartis proprietary antibody
US FDA approved weekly subcutaneous maintenance treatment with Leqembi® Iqlik™ for the treatment of early Alzheimer disease. An application for subcutaneous induction dosing with Leqembi Iqlik was initiated in the US
Leqembi approved in Australia, Bahrain, India, Kuwait and Saudi Arabia, and launched in Austria and Germany among others
Leqembi approved for IV maintenance treatment every four weeks in China, India, Qatar and the United Arab Emirates
Events after the end of the third quarter
Leqembi Iqlik launched for weekly maintenance dosing in the US
First patient treated with Leqembi in a private clinic in Finland
Leqembi approved in Canada
Financial summary July, September 2025
Net revenues amounted to SEK 133.3 M (76.6), of which SEK 117.2 M (69.8) in royalties for Leqembi and SEK 8.5M (-) from the agreement with Novartis
Operating profit amounted to SEK -28.8 M (-26.1)
Profit for the period amounted to SEK -86.9 M (-19.6)
Earnings per share before and after dilution amounted to SEK -0.98 (-0.22)
Cash flow from operating activities amounted to SEK -41.2 M (-80.3)
Cash and cash equivalents and short-term investments at the end of the period amounted to SEK 1,882.0 M (804.5)
Comments from the CEO"Our collaboration with Novartis marks an exciting new chapter for BioArctic"
Our journey into a new era and the work to meet our long-term ambitions continues, with several important milestones reached during the quarter. The progress made underscores our strong commitment to delivering innovative solutions that truly make a difference to patients' lives. Leqembi is becoming more and more established as a treatment for Alzheimer's disease, we have expanded our collaborations to include Novartis, and our pipeline continues to progress and has been broadened with new projects.
Leqembi sales continue to show good underlying growth globally of around 14 percent quarter on quarter, adjusted for the stocking effect seen in China in the second quarter. So far this year we have received royalties of SEK 376 M compared to SEK 134 M the first nine months of 2024, an increase of over 180 ...
